Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of PKN605, an oral medication, in adults with atrial fibrillation to see if it reduces the time spent in atrial fibrillation. This randomized, placebo-controlled, double-blind study aims to assess the treatments efficacy, safety, tolerability, and how the drug behaves in the body. The study is sponsored by Novartis Pharmaceuticals and focuses on participants with a history of atrial fibrillation. Participants will first undergo a screening period lasting up to 90 days to confirm eligibility. Once enrolled, they will be randomly assigned to receive either a lower or higher dose of oral PKN605 or a matching placebo. The treatment phase will last 24 weeks, with monthly clinic visits. Atrial fibrillation will be monitored throughout the study using various ECG devices. After treatment ends, there will be a final safety follow-up visit about one month later. During the study, participants will have regular assessments including ECG patch monitoring to measure atrial fibrillation burden, blood tests for drug levels, and other safety evaluations. Researchers will measure the time spent in atrial fibrillation and the time to first recurrence of atrial fibrillation after treatment begins. The total participation time includes screening, 24 weeks of treatment, and a safety follow-up visit approximately one month after treatment completion.
Actively Recruiting
Researchers are evaluating a shorter treatment duration with androgen receptor pathway inhibitors ARPIs, specifically Apalutamide or Enzalutamide, in patients with low-volume hormone-sensitive metastatic prostate cancer. This phase 3 clinical trial aims to determine if stopping ARPI therapy after 12 months, with the option to restart if the cancer progresses, is not worse than continuing ARPI treatment. The goal is to reduce side effects and costs while maintaining effective disease control. Participants will be randomly assigned after completing 12 months of ARPI treatment to one of two groups one group will continue androgen deprivation therapy ADT combined with ARPI, while the other will stop ARPI after 12 months but may restart it if a confirmed rise in prostate-specific antigen PSA occurs. The PSA confirmation sample must be taken at least four weeks after the initial rise. Treatment will be monitored closely according to these protocols. During the study, participants will be followed for up to 6 years, including 5 years after randomization to track clinical progression-free survival. Researchers will regularly assess disease status, treatment effects, and possible side effects. The study includes regular visits and monitoring to evaluate how long patients remain free from disease progression while comparing the two treatment approaches.
Actively Recruiting
Researchers are studying patients with non-metastatic stage II colon cancer who are part of the Dutch ColoRectal Cancer cohort PLCRC and who consented to additional blood samples. The study aims to evaluate how many patients with detectable circulating tumor DNA ctDNA after surgery begin adjuvant chemotherapy. This observational and interventional trial includes patients who do not have a standard indication for chemotherapy and involves a randomized design to compare ctDNA-guided treatment with standard care. Patients are randomly assigned to one of two groups the ctDNA-based treatment group or the standard care group. In the ctDNA group, blood samples taken after surgery are analyzed for ctDNA. Those with detectable ctDNA are offered 3 months of adjuvant chemotherapy using CAPOX a combination of fluoropyrimidine and oxaliplatin. Patients without detectable ctDNA receive routine follow-up care. The standard care group receives routine follow-up without knowledge of their ctDNA results. Participants will have blood collected before surgery, after surgery, and during follow-up. Researchers will monitor who starts chemotherapy within 8 to 12 weeks after surgery and will track recurrence rates, disease-free survival, overall survival, time to recurrence, quality of life, and cost-effectiveness over several years. Follow-up assessments occur up to 10 years, allowing detailed long-term evaluation of treatment impact and patient outcomes.
Actively Recruiting
This research aims to evaluate the continuation of the same systemic therapy after applying local ablative therapy LAT for patients with metastatic breast cancer that shows oligoprogression during palliative treatment. Oligoprogression is defined as limited progression in one or two lesions and this study focuses on patients with invasive breast cancer who have metastatic disease and are receiving systemic therapy. The study is a phase 2 interventional trial sponsored by The Netherlands Cancer Institute. Participants will receive local ablative therapy targeted at the progressing lesions, which may include surgery, stereotactic ablative radiotherapy SABR, or percutaneous radiofrequent ablation. The choice of LAT depends on the lesions location and will follow standard care decided by the treating team. The systemic therapy, which can be endocrine, targeted, chemotherapy, or immune-checkpoint blockade, will continue unchanged during the study. Throughout the study, patients will be monitored with imaging to confirm oligoprogression and assess lesion response. Outcome measures include the number of patients free of disease progression at 6 months, overall survival, time to next treatment, and complications from LAT. The study involves ongoing follow-up for up to 120 months to observe long-term outcomes. Participants will undergo radiological imaging, including FDG-PET-CT scans, and clinical assessments to track treatment effects and safety.
Actively Recruiting
Researchers are evaluating whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable circulating tumor DNA ctDNA after surgery. This trial focuses on improving disease-free survival by identifying patients at high risk of recurrence using ctDNA as a biomarker. The study is a randomized controlled trial conducted within a larger colorectal cancer cohort, aiming to clarify the benefit of adjuvant chemotherapy for this group of patients. Participants with detectable ctDNA after surgery are randomly assigned to either receive standard care or adjuvant chemotherapy, which involves 6 cycles of FOLFOX every 2 weeks or 4 cycles of CAPOX over 3 months. Chemotherapy is initiated within 8 to 12 weeks after surgery. The control group receives standard care without additional chemotherapy. The study also examines ctDNA clearance and its relationship with recurrence and survival. During the trial, participants will have blood samples taken regularly for ctDNA measurement and will complete quality of life questionnaires at multiple time points up to 4 years. Researchers will monitor disease-free survival and overall survival for up to 5 years. Safety is monitored through regular physician visits and blood tests during chemotherapy cycles. The total participation duration may last up to 10 years, including extended follow-up for survival and quality of life assessments.
Actively Recruiting
Researchers are evaluating chemotherapy dosing strategies in older patients aged 70 years and above who have metastatic colorectal cancer and are eligible for first-line palliative chemotherapy. This phase III randomized controlled trial aims to compare upfront dose-reduced chemotherapy with standard full-dose chemotherapy, focusing on progression-free survival PFS. Patients are assessed using the Geriatric 8 G8 questionnaire to determine their risk of chemotherapy toxicity, which guides treatment assignment. The study seeks to balance treatment effectiveness with minimizing toxicity, hospital admissions, and maintaining quality of life QoL and physical functioning. Participants classified as low risk for toxicity G8 score 15 or higher are randomized to receive either doublet chemotherapy a fluoropyrimidine combined with oxaliplatin at full dose or with a 25% dose reduction upfront. Those at high risk G8 score 14 or lower or judged high risk by their oncologist receive fluoropyrimidine monotherapy either at full dose or with a 25% dose reduction. The study also allows the addition of targeted treatments like bevacizumab or EGFR inhibitors. Dose adjustments are made for patients with moderate kidney impairment. Chemotherapy is given orally or intravenously on schedules varying between every two and three weeks, depending on the regimen. Participants will be closely monitored throughout treatment, with assessments including radiological or clinical evaluations for disease progression, quality of life and physical functioning questionnaires at 1, 3, 6, and 12 months, and tracking of chemotherapy toxicity, overall survival, treatment cycles, dose changes, hospital admissions, and cumulative drug dosage. Safety and cost-effectiveness will also be evaluated over an average study duration of eight months and up to one year for some outcomes. The study plans to include 587 patients and will continue until December 2028.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are investigating whether taking breaks from the standard combination therapy of daratumumab, lenalidomide, and dexamethasone Dara-Rd for newly diagnosed multiple myeloma patients affects survival and quality of life. This study aims to compare continuous treatment versus planned treatment-free intervals to see if stopping therapy temporarily may reduce side effects, allow recovery from toxicity, and improve overall well-being while controlling the disease. Participants who have completed 12 cycles of Dara-Rd with at least a partial response and no signs of disease progression will be randomly assigned to one of two groups. One group will continue Dara-Rd therapy without interruption until disease progression, while the other group will stop treatment temporarily and restart it at biochemical progression, continuing until disease progression. The trial is open-label and will follow patients for several years to assess outcomes. Throughout the study, researchers will monitor participants event-free survival and progression-free survival for up to about 57 and 69 months, respectively. Additional assessments include side effect burden, patient-reported quality of life, treatment costs, treatment-free interval length, response times, and survival after second-line therapy. Regular evaluations will help determine how treatment interruption affects toxicity, dose intensity, and overall treatment outcomes over the long term.
Actively Recruiting
Researchers are evaluating the benefits and costs of routine follow-up appointments after total hip or knee replacement surgery, particularly focusing on the 1-year follow-up visit. Current guidelines recommend follow-ups with X-rays at 3 months, 1 year, and then every 5 years for knee or hip replacements. However, these frequent visits may require significant time and resources from patients, caregivers, and healthcare providers, and it is unclear if all scheduled visits are necessary. The HAKA trial aims to safely reduce these routine follow-ups and update clinical guidelines accordingly. The trial compares two approaches one group receives standard care with X-rays and clinical visits at 3 months and 1 year after surgery, while the other group has the same 3-month visit but only a 1-year visit if requested by the patient or healthcare provider. This randomized study is part of a larger research program including long-term follow-up and qualitative studies about patient and provider experiences. Participants receive care following these schedules and are monitored over time. Participants will complete questionnaires assessing physical function, pain, and quality of life before surgery and at several intervals up to 24 months after surgery. Researchers will track the number of clinical visits, X-rays, complications, additional surgeries, and related costs during this period. The study monitors outcomes to evaluate whether reducing routine follow-ups is safe and cost-effective. Overall participation lasts about two years, with regular assessments to guide care decisions.
Actively Recruiting
Researchers are comparing robot-assisted radical prostatectomy RARP and external beam radiotherapy EBRT, sometimes combined with androgen deprivation therapy ADT, for men with high-risk non-metastatic prostate cancer. The study aims to understand differences in quality of life, functional outcomes, cost-effectiveness, progression-free survival, and distant metastasis-free survival. There is currently no clear consensus on which treatment is better, leading to variation in hospital practices. Participants will receive either RARP, which may include pelvic lymph node dissection and possibly adjuvant radiotherapy or androgen deprivation therapy, or EBRT delivered at an effective radiation dose, possibly combined with a brachytherapy boost and pelvic lymph node dissection. Positive lymph node findings will not exclude participants and may be treated with lymph node irradiation. Treatment details vary based on clinical decisions. During the study, participants will be followed for up to five years, with key assessments at three years including health-related quality of life and functional outcomes. Cost-effectiveness will also be evaluated at three years, while progression-free and distant metastasis-free survival will be tracked up to five years. The study involves regular monitoring to gather these outcomes and support shared decision-making for future patients.
1-10 of 18
1